December 18, 2024

Can Jardiance Slow Diabetic Eye Disease?

A recent report in JAMA Ophthalmology reveals that Jardiance, an oral diabetes drug, may help prevent worsening of diabetic eye disease in patients with type 2 diabetes, offering valuable insights for clinical management.

Reuters

December 16, 2024

Are Dietary Guidelines Built on Solid Research?

A study evaluating systematic reviews used to develop dietary guidelines for Americans revealed 'critically low' quality and significant methodological weaknesses, raising concerns about reliability and reproducibility.

Conexiant

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 16, 2024

Weight-Loss Drugs Spark Health Care Shift

An exclusive analysis reveals the impact of weight-loss drugs on obesity-related conditions, leading to increased diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes within days of treatment initiation.

Reuters

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

December 11, 2024

Fasting Glucose Rises Despite BMI Trends

A study analyzing trends in cholesterol, triglyceride, and glucose levels reveals concerning increases in fasting glucose levels and slowing improvements in cholesterol and triglyceride levels, underscoring the need for public health interventions.

Conexiant

December 11, 2024

Sex Differences in Statin-Linked Diabetes Risk

Study finds women are nearly twice as likely as men to report statin-associated diabetes mellitus, with atorvastatin showing the highest reporting disparity, according to Food and Drug Administration’s Adverse Event Reporting System data.

Conexiant

December 10, 2024

Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events

Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.

Conexiant